RPA1 and malignant colon neoplasm: In summary, increased level of secreted RPA1 protein was identified in this study as a prominent secretory feature of vemurafenib-resistant phenotype in BRAFV600E mutant colon cancer cells and detected in additional in silico analyses as a molecular trait of tumors from BRAFV600E-mutated colon cancer patients associated with unfavorable survival outcome.